Dissecting the FOXM1–Estrogen Receptor ceRNA Axis in Female Lung Adenocarcinoma

Study Background and Research Question

Lung adenocarcinoma (LUAD) constitutes a substantial proportion of lung cancer cases, particularly among females, and continues to be a major contributor to cancer-related mortality worldwide. Despite advancements in targeted therapeutics, overall survival rates for LUAD remain low, emphasizing the need for new molecular insights to guide prognosis and treatment strategies. The regulatory interplay between transcription factors, non-coding RNAs, and hormone receptors is increasingly recognized as pivotal in tumor biology. Among these, the transcription factor FOXM1 has been linked to oncogenesis and poor prognosis in several cancers, yet its functional interactions and downstream networks in female LUAD have remained incompletely characterized. The referenced study (Zhang et al., 2023) addresses this knowledge gap by investigating how FOXM1 interacts with estrogen receptor signaling and non-coding RNA networks to influence LUAD progression and immune landscape.

Key Innovation from the Reference Study

The central innovation of this work is the identification and mechanistic validation of a novel competitive endogenous RNA (ceRNA) network in female LUAD. This network consists of the long non-coding RNA DGCR-5, microRNA miR-204-5p, FOXM1, and estrogen receptor 1 (ESR1/ERα). By combining bioinformatic predictions with cellular validation, the study demonstrates that FOXM1 is not only overexpressed in LUAD but also physically and functionally linked to ERα signaling via a ceRNA regulatory axis. This ceRNA network is implicated in modulating tumor cell proliferation, apoptosis, and immune responsiveness, offering a new molecular framework for biomarker development and therapeutic targeting.

Methods and Experimental Design Insights

The study adopted a multi-tiered approach that integrated large-scale transcriptomic datasets, in silico network modeling, and experimental validation:

• Transcriptomic Analysis: Differentially expressed genes were identified using public LUAD datasets from GDC TCGA and GEO. Survival correlation and clinical association analyses provided links between gene expression and patient outcomes.
• MicroRNA and lncRNA Prediction: Target miRNAs and lncRNAs interacting with FOXM1 were predicted using miRDB, miRTarBase, and TargetScan, followed by co-expression analysis.
• ceRNA Network Construction: The predicted interactions were integrated into a ceRNA network using Cytoscape, focusing on DGCR-5, miR-204-5p, FOXM1, and ESR1.
• Functional Validation: Cellular experiments, including FOXM1 knockdown in LUAD cell lines, assessed effects on proliferation and apoptosis. Luciferase reporter assays and RNA immunoprecipitation confirmed direct interactions within the network.
• Immunological Profiling: Analysis of tumor mutational burden and immune cell infiltration (via GSEA) evaluated the relationship between FOXM1 expression and immunotherapy sensitivity.

Core Findings and Why They Matter

Key findings from the study include:

• FOXM1 Overexpression: FOXM1 is significantly upregulated in LUAD tissues compared to normal lung, correlating with poorer survival and more aggressive clinical features.
• Functional Impact of FOXM1 Knockdown: Reducing FOXM1 levels in vitro led to suppressed LUAD cell proliferation and increased apoptosis, supporting its role as a tumor promoter.
• ceRNA Network Elucidation: The network DGCR-5–miR-204-5p–FOXM1–ERα was established and validated. miR-204-5p directly targets FOXM1, while DGCR-5 does not directly interact with miR-204-5p in this axis. Importantly, FOXM1 and ERα physically interact, suggesting a convergence of proliferation and hormone signaling pathways.
• Immunotherapy Implications: Tumors with low FOXM1 expression showed increased sensitivity to immune checkpoint inhibitors (anti-PD1 and anti-CTLA4), with distinct patterns of immune cell infiltration, highlighting FOXM1 as a potential biomarker for immunotherapy stratification.

These findings collectively underscore the mechanistic and clinical importance of integrated transcriptional and hormonal networks in female LUAD. The work provides a foundation for personalized biomarker development and suggests new angles for combining hormone receptor modulation with immunotherapeutic strategies.

Comparison with Existing Internal Articles

This reference study builds upon and extends concepts discussed in previous internal resources:

• The article "FOXM1–Estrogen Receptor ceRNA Network in Female Lung Adenocarcinoma" offers an overview of transcriptomic and bioinformatic methods for ceRNA network identification in LUAD, which aligns with the experimental approach in the reference study.
• Recent work, such as "FOXM1–ERα ceRNA Network as a Prognostic Axis in Female LUAD", underscores the prognostic and therapeutic relevance of FOXM1–ERα interactions, supporting the reference paper's conclusions about biomarker potential and immune contexture.
• In the context of estrogen receptor signaling, internal reviews like "PPT (Propyl Pyrazole Triol): Dissecting Estrogen Receptor..." discuss the utility of selective ERα agonists to experimentally probe hormone receptor function and downstream gene expression, which is directly relevant to modeling the ERα axis in LUAD.

Thus, the current study provides direct experimental validation and a more comprehensive integration of immune and ceRNA network analysis than previously reported, offering a richer mechanistic context for future research.

Limitations and Transferability

While the study offers robust multi-omics and cellular validation, certain limitations merit consideration:

• Cohort Specificity: The analyses focus on female LUAD samples; extrapolation to male patients or other lung cancer subtypes should be done cautiously.
• In Vitro Model Constraints: Functional assays were performed in cell lines, which may not fully recapitulate the tumor microenvironment or complex immune interactions observed in vivo.
• Mechanistic Scope: While a physical interaction between FOXM1 and ERα is demonstrated, the precise biochemical details and downstream transcriptional effects require further elucidation.

Despite these constraints, the ceRNA network and biomarker findings offer a promising platform for translational studies, especially in the context of personalized medicine and immunotherapy response prediction.

Protocol Parameters

• Cell line selection: Use LUAD cell lines with verified ERα and FOXM1 expression for functional assays.
• Gene knockdown/overexpression: Apply siRNA or shRNA systems for FOXM1 suppression; confirm efficiency with qPCR and Western blot.
• Reporter assays: Utilize luciferase constructs containing FOXM1 3'UTR to assess miR-204-5p targeting activity.
• Co-immunoprecipitation: Perform to validate physical FOXM1–ERα interaction in nuclear extracts.
• Immunotherapeutic assessment: Stratify samples by FOXM1 expression for immune checkpoint inhibitor sensitivity analysis.

Research Support Resources

To experimentally dissect ERα-mediated gene expression and hormone receptor signaling in LUAD or related cancer models, researchers may employ PPT (Propyl Pyrazole Triol), a potent, selective ERα agonist (SKU B6735). Its high selectivity for ERα over ERβ makes it an effective tool for parsing estrogen receptor subtype functions in vitro and in vivo. For detailed protocols and further background, the APExBIO product dossier provides solubility, storage, and application guidelines. Use of such reagents should always be contextually matched with the experimental objectives and validated against appropriate controls.